College of American Pathologists
CAP Committees & Leadership CAP Calendar of Events Estore CAP Media Center CAP Foundation
 
About CAP    Career Center    Contact Us      
Search: Search
  [Advanced Search]  
 
CAP Home CAP Advocacy CAP Reference Resources and Publications CAP Education Programs CAP Accreditation and Laboratory Improvement CAP Members
CAP Home > CAP Reference Resources and Publications > FNA or core needle biopsy? Why not both?

  FNA or core needle biopsy? Why not both?

title

 

 

 

November 2007
PAP/NGC Programs Review

Camilla J. Cobb, MD

Like other initially competing methods, fine-needle aspiration and core needle biopsy have achieved not only individual but also combined utility in the diagnosis of mass lesions. Fine-needle aspiration, or FNA, is quick, safe, accurate, and inexpensive, and outcomes compare well with the results of tissue biopsy when the FNA is performed and interpreted by skilled individuals.1-5 However, with fewer skilled individuals performing and interpreting the FNAs and making themselves available for on-site adequacy assessment, the use of core needle biopsy, or CNB, has increased, for not only deep-seated nonpalpable lesions but also for palpable masses in the breast, thyroid, lymph nodes, and soft tissue. This shift was welcomed (and in some cases encouraged) by many pathologists, whose training in anatomic pathology and daily work consists mainly of surgical pathology, which brings in considerably more revenue than comparable time spent on cytopathologic activities.

CNB procedures are usually performed by radiologists, who are also trained to perform FNAs but who will generally provide the specimen type that the pathologists prefer, and in recent times that specimen is often a CNB. The Catch-22 in this, so to speak, or the unanticipated outcome, is that radiologists are not simply dropping the cores into formalin and sending them to the pathology laboratory for processing and interpretation the next day. As with the FNA, radiologists also want an adequacy assessment on the CNB. Like the FNA, CNBs are time-consuming procedures (for the radiologist, not the pathologist) that, even for palpable lesions, are usually performed with image guidance. The CNB is also expensive and time-consuming for patients and is uncomfortable as well. Also like the FNA, CNBs, even with image guidance, can "miss" the lesion. Radiologists, therefore, want to ensure that the CNB is adequate and that any specimen triage needed (for example, for microbiologic culture or flow cytometry) is accomplished during the single procedure. Adequacy assessment of a CNB is, therefore, reasonable, and pathologists, despite their grumblings, are generally complying with this new responsibility.

Unfortunately for some pathologists, assessing the adequacy of a CNB is more challenging than assessing the adequacy of an FNA sample. Problems are related to the nature of cell transfer from the CNB to the glass slide, which is accomplished by (gently) making multiple touches of the core to the slide or (gently) rolling the core over the slide. Compared with an FNA specimen, these procedures typically transfer significantly fewer cells and can cause cellular distortion and promote air-drying, which challenge adequacy assessment and specimen triage. Furthermore, the physical manipulation of the tissue core and the delay in placing the small core into fixative sometimes lead to tissue disruption and poor preservation that can cause difficulty in histologic interpretation.

No doubt, a well-sampled CNB specimen usually has greater diagnostic accuracy and provides more tissue for ancillary testing compared with the typical FNA sample,1,2,6,7 but the manipulations required to assess the adequacy of the CNB can compromise the interpretive outcome significantly, yielding equivocal diagnoses. After a period of struggle at my own institution, our pathologists and radiologists collectively found a solution to this dilemma. When the pathologist is called upon to assist a radiologist in the minimally invasive retrieval of tissue for diagnosis, an FNA is done initially for adequacy assessment, followed by CNB, only if (based on adequacy assessment) additional tissue is needed. We find this to be an efficient and cost-effective approach that also parallels a recent shift in the literature from the almost exclusive advocation of CNB over FNA to a renewed recognition of the benefits of FNA, including the value of FNA compared to, and combined or in tandem with, CNB.1,3-5,7,8-18 Thus, should you encounter problems regarding the utility of FNA versus CNB, a discussion among pathologists and radiologists about the advantages of doing both may be helpful. A reasonable alternative, if it is possible, is to limit adequacy evaluations of CNBs and FNAs to pathologists in the group who practice cytopathology.

References

  1. Quinn SF, Nelson HA, Demlow TA. Thyroid biopsies: fine-needle aspiration biopsy versus spring-activated core biopsy needle in 102 patients. J Vasc Interv Radiol. 1994;5:619-623.
  2. Ballo MS, Sneige N. Can core needle biopsy replace fine-needle aspiration cytology in the diagnosis of palpable breast carcinoma: A comparative study of 124 women. Cancer. 1998;78:773-777.
  3. Greif J, Marmur Y, Schwarz A, et al. Percutaneous core cutting needle biopsy compared with fine-needle aspiration in the diagnosis of peripheral lung malignant lesions. Cancer Cytopathology. 2000;84:144-147.
  4. Stewart CJR, Coldewey J, Stewart IS. Comparison of fine-needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol. 2002;55:93-97.
  5. Berner A, Davidson B, Sigstad E, et al. Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions. Diagn Cytopathol. 2003;29:344-348.
  6. Yang YJ, Damron TA. Comparison of needle core biopsy and fine-needle aspiration for diagnostic accuracy in musculoskeletal lesions. Arch Pathol Lab Med. 2004;128:759-764.
  7. Renshaw AA, Pinnar N. Comparison of thyroid fine-needle aspiration and core needle biopsy. Am J Clin Pathol. 2007;128:370-374.
  8. Malmstrom H. Fine-needle aspiration cytology versus core biopsies in the evaluation of recurrent gynecologic malignancies. Gynecol Oncol. 1997;65:69-73.
  9. Staroselsky AN, Schwarz Y, Man A, et al. Additional information from percutaneous cutting needle biopsy following fine-needle aspiration in the diagnosis of chest lesions. Chest. 1998;113:1522-1525.
  10. Yamagami T, Iida S, Kato T, et al. Combining fine-needle aspiration and core biopsy under CT fluoroscopy guidance: A better way to treat patients with lung nodules? AJR. 2003;180:811-815.
  11. Chiu S, Chan LK. US-guided biopsy of breast lesions: FNA vs. core biopsy. Biomed Imaging Interv J. 2005;1:e6-4.
  12. Yun G, Sneige N, Ming G, et al. Transthoracic fine-needle aspiration vs concurrent core needle biopsy in diagnosis of intrathoracic lesions: A retrospective comparison of diagnostic accuracy. Am J Clin Pathol. 2006;125:438-444.
  13. Singh HK, Volmar KE, Elsheikh TM, et al. The diagnostic utility of fine-needle aspiration biopsy of soft-tissue sarcomas in the core needle biopsy era. Pathology Case Reviews. 2007;12:36-43.
  14. Silverman JF, Elsheikh TM, Singh HK. The role of fine needle aspiration cytology of the breast in the core biopsy era. Pathology Case Reviews. 2007;12:44-48.
  15. Elsheikh TM, Singh HK, Silverman JF. Fine-needle aspiration cytology versus core needle biopsy in the evaluation of thyroid and salivary gland lesions. Pathology Case Reviews. 2007;12:3-9.
  16. Volmar KE, Singh HK, Gong JZ. The advantages and limitations of the role of core needle and fine-needle aspiration biopsy of lymph nodes in the modern era. Pathology Case Reviews. 2007;12:10-26.
  17. Volmar KE, Singh HK, Gong JZ. Fine-needle aspiration biopsy of lymph nodes in the modern era: reactive lymphadenopathies. Pathology Case Reviews. 2007; 12:27-35.
  18. Diacon AH, Theron J, Schubert P, et al. Ultrasound-assisted transthoracic biopsy: fine-needle aspiration or cutting-needle biopsy? Eur Respir. 2007;29:357-362.

Dr. Cobb, a member of the CAP Cytopathology Committee, is assistant director of cytopathology and director of cytopathology fellowship, Department of Pathology, Loma Linda (Calif.) University Medical Center.

 
 
 © 2014 College of American Pathologists. All rights reserved. | Terms and Conditions | CAP ConnectFollow Us on FacebookFollow Us on LinkedInFollow Us on TwitterFollow Us on YouTubeFollow Us on FlickrSubscribe to a CAP RSS Feed